Urogenital System (e.g., Kidney, Etc.) Patents (Class 424/558)
  • Patent number: 11767498
    Abstract: An in vitro tissue plate may include a well plate, a fluidic plate disposed on a bottom surface of the well plate, and a media manifold disposed on a bottom surface of the fluidic plate. The well plate may have at least two wells, including a tissue well and a waste well. The fluid plate may include a fluid channel extending between and fluidly connecting the tissue well to the waste well. The media manifold may include a one or more media outlets fluidly connected to the fluid channel. A tissue layer may be deposited in the tissue well. The tissue layer may include human cells such as neurovascular cells.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 26, 2023
    Assignees: Massachusetts Institute of Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Johanna Bobrow, Todd Thorsen, David Walsh, Christina Zook, Min Jae Song, Marc Ferrer-Alegre, Sam Michael, Yen-Ting Tung, Molly Elizabeth Boutin
  • Patent number: 11571446
    Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 7, 2023
    Assignees: Sanford Bumham Prebys Medical Discovery Institute, Technion Research & Development Foundation Ltd.
    Inventors: Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze'ev Ronai, Shiri Ashkenazi
  • Patent number: 11491191
    Abstract: A cosmetic or dermatological preparation that contains an aqueous and a lipophilic fish egg extract for replumping skin; for increasing the incorporation of triglycerides in adipocytes; for increasing the expression of laminin, preferably of laminin-5 and most preferably of laminin-5 ? sub-unit; and/or for maintaining the skin elasticity and/or resilience of human skin.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 8, 2022
    Assignee: LA PRAIRIE GROUP AG
    Inventors: Daniel Stangl, Bernhard Dudler
  • Patent number: 10993973
    Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 4, 2021
    Assignee: Glac Biotech Co., Ltd.
    Inventors: Pei-Shan Hsieh, Yi-Chun Tsai, Chung-Wei Kuo, Hsieh-Hsun Ho, Hung-Chih Lin, Jiu-Yao Wang
  • Patent number: 10906679
    Abstract: The present disclosure provides a variety of methods and compositions useful for making, sterilizing, and preserving tissues. The disclosure also features the acellular tissue matrices made by the methods.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 2, 2021
    Assignee: LifeCell Corporation
    Inventors: Wendell Sun, Jerome Connor, Qing-Qing Qiu, Rick T. Owens
  • Patent number: 10105397
    Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: October 23, 2018
    Assignee: MiMedx Group, Inc.
    Inventors: Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
  • Patent number: 9657265
    Abstract: The present invention provides constructs including a tubular biodegradable polyglycolic acid scaffold, wherein the scaffold may be coated with extracellular matrix proteins and substantially acellular. The constructs can be utilized as an arteriovenous graft, a coronary graft, a peripheral artery bypass conduit, or a urinary conduit. The present invention also provides methods of producing such constructs.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: May 23, 2017
    Assignee: Humacyte, Inc.
    Inventors: Shannon L. M. Dahl, Laura E. Niklason, Juliana Blum, Justin T. Strader, William E. Tente, Heather L. Prichard, Joseph J. Lundquist
  • Patent number: 9597429
    Abstract: The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: March 21, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Christine E. Schmidt, Terry Hudson
  • Patent number: 9427000
    Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: August 30, 2016
    Assignee: Mars, Incorporated
    Inventors: Thomas William-Maxwell Boileau, Barry Pius Kiley, Liam Diarmuid O'Mahony, John MacSharry, Gregory Dean Sunvold
  • Patent number: 9259441
    Abstract: Discloses a novel synergistic herbal composition comprising combination of therapeutically effective amount of Vrun bhavit, Kadalikshar, Apamargkshar, Yavkshar and optionally Gomutrakshar along with pharmaceutical acceptable additives, useful for the treatment of kidney stone and other urinary disorders like inflammation and urinary stent related problems.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 16, 2016
    Inventor: Suresh Balkrishna Patankar
  • Patent number: 9180143
    Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularization is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 10, 2015
    Assignee: Tissue Regenix Limited
    Inventors: Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
  • Publication number: 20150110754
    Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 23, 2015
    Inventors: Yu Bai, Wen Fury
  • Patent number: 8992996
    Abstract: A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: March 31, 2015
    Assignee: Restorsea, LLC
    Inventors: Enrique P. Alabata, Patricia S. Pao
  • Publication number: 20150050359
    Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 19, 2015
    Inventors: Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
  • Publication number: 20150037416
    Abstract: A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 5, 2015
    Inventors: Clay Fette, Abram Janis, Benjamin Kibalo
  • Publication number: 20150018966
    Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 15, 2015
    Inventors: Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
  • Publication number: 20140342007
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Application
    Filed: July 16, 2014
    Publication date: November 20, 2014
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Publication number: 20140335046
    Abstract: A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target skin location on the subject to induce an inciting event, and (iii) administering a therapeutically effective amount of said ECM composition to the target skin location. In some embodiments, the ECM composition includes at least one additional biologically active agent.
    Type: Application
    Filed: September 19, 2013
    Publication date: November 13, 2014
    Inventor: Robert G. Matheny
  • Publication number: 20140271778
    Abstract: Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated.
    Type: Application
    Filed: April 14, 2014
    Publication date: September 18, 2014
    Applicant: Advanced Technologies and Regenerative Medicine LLC
    Inventors: Charito S. Buensucceso, David C. Colter, Brian C. Kramer, Agnieszka Seyda
  • Patent number: 8828448
    Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularization is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: September 9, 2014
    Assignee: Tissue Regenix Limited
    Inventors: Sotirios Korossis, Eileen Ingham, Fiona Bolland, Jennifer Southgate
  • Publication number: 20140242184
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 28, 2014
    Inventor: Robert G Matheny
  • Patent number: 8808721
    Abstract: The present invention relates to compositions and methods for attracting bed bugs with novel attractants and new and improved methods to enable their use to attract, monitor or trap bed bugs for surveying, monitoring, mitigation and management purposes. Known mammal pheromones were discovered to be useful as bed bug kairomone attractants. A method of delivering non-volatile attractants by using the attractive heat source to heat and volatilize the attractants was discovered to be the optimal method to disseminate the kairomones. A new method of generating low levels of carbon dioxide is disclosed, and the combination of kairomones, carbon dioxide and heat is shown to attract bed bugs.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: August 19, 2014
    Assignee: SpringStar Inc.
    Inventors: Michael Gilbert Banfield, Elizabeth Joy Schaafsma
  • Publication number: 20140227364
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Publication number: 20140220095
    Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties.
    Type: Application
    Filed: January 24, 2014
    Publication date: August 7, 2014
    Applicant: LifeCell Corporation
    Inventors: Gary Monteiro, Christopher T. Wagner, Neil L. Rodriguez, Aubrey Irene Delossantos
  • Publication number: 20140134264
    Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD133+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).
    Type: Application
    Filed: December 2, 2013
    Publication date: May 15, 2014
    Applicant: Fresenius Medical Care Deutschland GmbH
    Inventors: Vincenzo CANTALUPPI, Maria Deregibus, Giovanni Camussi
  • Publication number: 20140112890
    Abstract: The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency.
    Type: Application
    Filed: April 2, 2012
    Publication date: April 24, 2014
    Applicant: The John Hopkins University
    Inventors: Jennifer H. Elisseeff, Iossif Strehin
  • Patent number: 8691276
    Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: April 8, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Donald Freytes
  • Publication number: 20140088339
    Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.
    Type: Application
    Filed: March 1, 2013
    Publication date: March 27, 2014
    Applicant: Francis Law Group
    Inventor: Robert Matheny
  • Patent number: 8673851
    Abstract: The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these synapse-specific proteins results in modulation of podocytes.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: March 18, 2014
    Assignee: Fondazione d'Amico per la Ricerca Sulle Malattie Renali
    Inventor: Maria P. Rastaldi
  • Patent number: 8647677
    Abstract: A cell culture growth substrate comprising submucosal tissue of a warm-blooded vertebrate and a method for culturing fastidious organisms is described. Submucosal tissue used in accordance with the present invention supports the proliferation of cells when said cells are contacted with submucosal tissue under conditions conducive to cell proliferation.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: February 11, 2014
    Assignee: Purdue Research Foundation
    Inventors: Stephen F. Badylak, Sherry L. Voytik-Harbin, Matthew S. Waninger, Andrew O. Brightman
  • Publication number: 20130243738
    Abstract: The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 19, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Leigh G. GRIFFITHS, Angeliki PAPALAMPROU, Maelene L. WONG
  • Publication number: 20130236453
    Abstract: Methods and compositions for treating or preventing acute graft-versus-host disease (aGVHD) in a subject using miR-155 specific inhibitors are described.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 12, 2013
    Applicant: THE OHIO STATE UNIVERSITY
    Inventors: Carlo M. Croce, Ramiro Garzon
  • Publication number: 20130129833
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Application
    Filed: January 2, 2013
    Publication date: May 23, 2013
    Inventor: Robert G. Matheny
  • Publication number: 20130129834
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Application
    Filed: January 2, 2013
    Publication date: May 23, 2013
    Applicant: Francis Law Group
    Inventor: Francis Law Group
  • Patent number: 8415159
    Abstract: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 9, 2013
    Assignee: Mesynthes Ltd.
    Inventors: Brian Roderick Ward, Keryn Dallas Johnson, Barnaby Charles Hough May
  • Patent number: 8361503
    Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: January 29, 2013
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Donald O. Freytes
  • Publication number: 20120225056
    Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 6, 2012
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Camille Bedrosian, Stephen P. Squinto, Leonard Bell
  • Publication number: 20120226218
    Abstract: Extracellular matrix material is disclosed which is created by subjecting a target area to non-thermal irreversible electroporation (NTIRE) with a pulsed electrical field to kill cells in the absence of thermal damage. The dead cellular material may be removed and the remaining non-cellular matrix material may be implanted into a repair site to be treated medically or cosmetically.
    Type: Application
    Filed: September 2, 2010
    Publication date: September 6, 2012
    Inventors: Mary Phillips, Elad Maor, Boris Rubinsky, Jacob Lavee
  • Publication number: 20110262498
    Abstract: Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject.
    Type: Application
    Filed: December 4, 2009
    Publication date: October 27, 2011
    Applicant: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Thomas Gilbert, Michelle Manni, Tim D. Oury
  • Publication number: 20110083201
    Abstract: The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B inhibitory serpin, methods for treating a patient in need of immunosuppression by administration of a granzyme B inhibitory serpin, and methods of transplanting cells (e.g., islet cells) expressing a granzyme B inhibitory serpin.
    Type: Application
    Filed: September 7, 2010
    Publication date: April 7, 2011
    Inventors: Ray V. Rajotte, R. Chris Bleackley, Greg Korbutt, Sarah J. Lord, Simonetta Sipione, Katia Carmine-Simmen, Fabrizio Giuliani
  • Publication number: 20100221310
    Abstract: Described, in certain aspects, are medical products comprised of uniquely prepared remodelable extracellular matrix (ECM) materials retaining at least a portion of their native bioactivity. Also described are methods for forming and using such products. In one embodiment, an inventive product comprises a layer of remodelable ECM material modified through contact with periodic acid or a salt thereof. In some forms, such a modified ECM material layer includes non-native Schiff's base crosslinks within and/or between certain components of the ECM material (e.g., between two collagen molecules, two non-collagen molecules, and/or a collagen molecule and a non-collagen molecule). Other inventive products are comprised of various gels, foams, pastes, and formed, coherent, porous bodies at least containing ECM materials that have been modified in accordance with the present invention.
    Type: Application
    Filed: May 14, 2010
    Publication date: September 2, 2010
    Inventor: Joel A. Virkler
  • Patent number: 7785635
    Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Lactobacilli.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: August 31, 2010
    Assignee: The Procter & Gamble Company
    Inventors: Thomas William-Maxwell Boileau, Michael Anthony Ceddia, Gary Mitchell Davenport, Barry Pius Kiely, Liam Diarmuid O'Mahony, Gregory Dean Sunvold, Mark Alan Tetrick, Robert Jason Vickers
  • Patent number: 7780992
    Abstract: There is disclosed a prophylactic and therapeutic antiviral composition and in particular compositions which comprise containing vertebrates kidney as a main component. Use of the composition through parenteral administration for the prevention and treatment of viral-induced tumors, lesions and diseases in mammals such as humans or to prepare a medicament is also disclosed. The composition is very effective in preventing and treating viral infections and manifestations as hyperplasia, keratosis, and dermatosis and in particular those caused by Papillomavirus and more particularly Human Papillomavirus. Among the many benefits, the present compounds provide high remedial effect and complete resolution in a relatively short course of treatment with no risk of side effects what so ever. The composition is abundant, inexpensive, easily prepared, and may be self administered to the afflicted area by the patients themselves.
    Type: Grant
    Filed: December 8, 2002
    Date of Patent: August 24, 2010
    Inventor: Tareq Abduljalil Albahri
  • Patent number: 7776596
    Abstract: A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of urinary bladder submucosa and stomach submucosa, and extracts and hydrolysates thereof, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance initiation of the formation vessel-like structures in the graft construct. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally-derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods for enhancing the vascularization in vivo of these tissue graft constructs and for preparing these graft constructs are also provided.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: August 17, 2010
    Assignee: Purdue Research Foundation
    Inventor: Stephen F. Badylak
  • Publication number: 20090324607
    Abstract: A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.
    Type: Application
    Filed: January 19, 2006
    Publication date: December 31, 2009
    Applicant: Yeda Research And Development Co. Ltd.
    Inventors: Yair Reisner, Benjamin Dekel, Smadar Eventov-Friedman, Helena Katchman, Elias Shezen, Anna Aronovich, Dalit Tchorsh
  • Publication number: 20090297622
    Abstract: A pharmaceutical composition includes an effective amount of bio-active fraction PMF or subfraction PMFK obtained from the lyophilized camel urine or cow urine which coded in publications with PM701, that is used as anti-cancer drug selected from an anticancer compound PM701, which are targeted selectively the cancer cells without affecting the normal cells.
    Type: Application
    Filed: July 23, 2008
    Publication date: December 3, 2009
    Inventor: Faten A. Khorshid
  • Publication number: 20090186006
    Abstract: The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 23, 2009
    Inventor: Michael P. Murphy
  • Publication number: 20090142409
    Abstract: The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 4, 2009
    Inventors: Leigh H. Firestone, Robert G. Matheny
  • Publication number: 20090130221
    Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.
    Type: Application
    Filed: March 28, 2007
    Publication date: May 21, 2009
    Inventors: Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
  • Patent number: 7485855
    Abstract: A system and method for cleanup of biological samples from contaminants prior to spectroscopy analysis. The system includes a support configured to hold a sample including a liquid having at least one group of biological molecules with a surface of the support binding the molecules at a surface tension angle to the liquid of less than 180 degrees. The system includes an evaporator configured to evaporate liquid from the support, a solvent applicator configured to apply a solvent for dissolution of the contaminants in the sample, and a solvent removal device configured to remove applied solvent from the sample and thereby at least partially remove the contaminants.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 3, 2009
    Assignee: Science and Engineering Services, Inc.
    Inventors: Appavu K. Sundaram, Nelli I. Taranenko, Vladimir M. Doroshenko